Navigation Links
Genetic Immunity to Present at 2008 BIO International Convention
Date:6/12/2008

MCLEAN, Va. and BUDAPEST, Hungary, June 12 /PRNewswire/ -- Genetic Immunity, a US/Hungarian clinical-stage Company focused on the development of its patented nanomedicines for targeted immune amplification, announced today that the Company will be presenting at the 2008 Bio International Convention to be held June 17-20, 2008 at the San Diego Convention Center in San Diego, CA. The Company's President and Chief Executive Officer, Dr. Julianna Lisziewicz, is scheduled to present at the following times:

-- Wednesday, May 18 at 2:00 p.m. (PT): Dr. Lisziewicz will present an

overview of Genetic Immunity's nanomedicine technology platform and

clinical programs on as part of the infectious disease tract in room

5B.

-- Thursday, June 19th at 2:00 p.m. (PT): Dr. Lisziewicz will represent

Genetic Immunity in an international case study, "Biotechnology in

Hungary: Mission Possible," in room 26 AB.

For more information on this event please visit: http://www.bio2008.org.

While at the conference Genetic Immunity will discuss three partnering opportunities. The first is focused on DermaVir Patch, which is the Company's lead nanomedicine candidate for the treatment for HIV/AIDS. This topically delivered nanomedicine is designed to amplify HIV-specific memory T cell responses in order to kill HIV-infected cells specifically while leaving the healthy cells intact.

The second opportunity is DermaPrep, which is a novel and proprietary medical device that supports the topical delivery of macromolecules to lymph nodes. DermaPrep is designed to mimic the body's response and has demonstrated proof of concept with through development of the DermaVir Patch.

The third partnering option is the Company's patented NanoComp nanoformulation technology that includes disease-specific, plasmid DNA-encoded antigens. It is designed to improve the immunigenicity of antigens and induce effective immune responses. NanoComp has also demonstrated proof of concept with the DermaVir Patch, which includes HIV-specific plasmid DNA encoded antigens.

About Genetic Immunity(R)

Genetic Immunity is a US/Hungarian clinical stage biopharmaceutical company establishing leadership in Nanomedicines for targeted immune amplification. Nanomedicine, an offshoot of nanotechnology, refers to highly specific medical intervention at the molecular scale for curing diseases or repairing damaged tissues. The Company aims to discover, develop and commercialize topically administered nanomedicines that can create new markets for treating infectious diseases, cancer and allergies. These indications represent a significant unmet medical need and the potential for alternative treatment approaches. The DermaVir Patch, Genetic Immunity's lead nanomedicine candidate, is in Phase II clinical development and could be the first nanomedicine immune therapy for HIV-infected individuals. The DermaVir Patch has demonstrated excellent safety, immunogenicity and antiviral efficacy in preclinical studies. Phase I/II trials to date have confirmed safety and tolerability and indicate the induction of long-lasting HIV-specific memory T cells.

About the Nanomedicine Technology Platform

Genetic Immunity's nanomedicine immune amplification platform technology is comprised of two principal components: NanoComp and DermaPrep. NanoComp is a patented nanoformulation technology that includes disease-specific plasmid DNA encoded antigens. DermaPrep is the topical administration device that delivers NanoComp into a patient's lymph node dendritic cells to induce T cell mediated immune responses that can treat a broad spectrum of diseases. These two components together make up the DermaVir Patch. The plasmid DNA within DermaVir Patch's NanoComp nanoparticles is specific to HIV and topically delivered via DermaPrep to amplify the immune system to kill only HIV-infected cells.

Contacts:

The Ruth Group

Investors

Sara Ephraim

+1-646-536-7002

sephraim@theruthgroup.com

Media

Janine McCargo

+1-646-536-7033

jmccargo@theruthgroup.com

http://www.geneticimmunity.com


'/>"/>
SOURCE Genetic Immunity
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Targeted Genetics Announces Positive Phase 1/2 tgAAC94 Data Presented at Annual European Congress of Rheumatology
2. Genetic Engineering & Biotechnology News Reports on the Growing Role of Ion-Channel Studies in Global Biotech R&D
3. CellCyte Genetics Corporation Selects Washington University School of Medicine to Perform Study on CellCytes Glycoprotein Products in Heart Attack Disease Model
4. Presentation of Data on Progens Cancer Epigenetic Targets Platform
5. CellCyte Genetics Signs Collaborative Agreement With Northwestern Universitys Feinberg School of Medicine to Perform Disease Model Outcome Study of CellCytes CCG-TH30 Product Candidate
6. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
7. deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer
8. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
9. Genetic Immunity Announces Data Related to the DermaVir Nanomedicine Patch in the Journal of Immunology
10. Preclinical Study Shows CTIs Brostallicins Cancer-Killing Ability Based on Genetic Profiling
11. Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... CAMBRIDGE, Mass. , Dec. 8, 2016 /PRNewswire/ ... today that Nationwide Children,s Hospital signed ... enhance and accelerate the development of new cures. ... healthcare organizations representing over 57 million patients globally, ... are working together to improve protocol design, site ...
(Date:12/8/2016)... Dec. 8, 2016 True Health Diagnostics ... leading-edge laboratory services and management expertise to hospital ... , allowing more doctors and patients to benefit ... solutions. Logo - http://photos.prnewswire.com/prnh/20161208/447162LOGO ... systems, under pressure to contain costs, have struggled ...
(Date:12/8/2016)... 8, 2016 Research and Markets has announced ... their offering. ... The global chromatography market to grow at a ... Market 2016-2020, has been prepared based on an in-depth market analysis with ... growth prospects over the coming years. The report also includes a discussion ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... December 08, 2016 , ... Russ DiGilio ... the first national #QuackGivesBack campaign which supported local breast cancer organizations during National ... Quack Gives Back initiative, and we’re very pleased with the participation ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... County, a Property owned by an affiliate of Seavest, has won a prestigious ... Medicine Southern Chester County ambulatory care center (ACC) was named “Best New Development, ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s leading digital ... aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced CURE Media ... Jr said, “CURE Media Group is honored to team up with Upstage Lung Cancer ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , Ginger ... Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont Newport ... attorneys from the firm’s global Life Sciences & Medical Technology Group have been featured ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... modes of access for customers and employees that are both engaging and easy ... with Service Smart Technology, the software company revealed today its plans to roll ...
Breaking Medicine News(10 mins):